Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model
- PMID: 22101761
- DOI: 10.1007/s10928-011-9228-y
Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model
Abstract
The paper compares performance of Nonmem estimation methods--first order conditional estimation with interaction (FOCEI), iterative two stage (ITS), Monte Carlo importance sampling (IMP), importance sampling assisted by mode a posteriori (IMPMAP), stochastic approximation expectation-maximization (SAEM), and Markov chain Monte Carlo Bayesian (BAYES), on the simulated examples of a monoclonal antibody with target-mediated drug disposition (TMDD), demonstrates how optimization of the estimation options improves performance, and compares standard errors of Nonmem parameter estimates with those predicted by PFIM 3.2 optimal design software. In the examples of the one- and two-target quasi-steady-state TMDD models with rich sampling, the parameter estimates and standard errors of the new Nonmem 7.2.0 ITS, IMP, IMPMAP, SAEM and BAYES estimation methods were similar to the FOCEI method, although larger deviation from the true parameter values (those used to simulate the data) was observed using the BAYES method for poorly identifiable parameters. Standard errors of the parameter estimates were in general agreement with the PFIM 3.2 predictions. The ITS, IMP, and IMPMAP methods with the convergence tester were the fastest methods, reducing the computation time by about ten times relative to the FOCEI method. Use of lower computational precision requirements for the FOCEI method reduced the estimation time by 3-5 times without compromising the quality of the parameter estimates, and equaled or exceeded the speed of the SAEM and BAYES methods. Use of parallel computations with 4-12 processors running on the same computer improved the speed proportionally to the number of processors with the efficiency (for 12 processor run) in the range of 85-95% for all methods except BAYES, which had parallelization efficiency of about 70%.
Similar articles
-
Evaluation of FOCEI and SAEM Estimation Methods in Population Pharmacokinetic Analysis Using NONMEM® Across Rich, Medium, and Sparse Sampling Data.Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):729-736. doi: 10.1007/s13318-018-0484-8. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29785609
-
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003. Clin Pharmacokinet. 2006. PMID: 16584284
-
Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.BMC Med Res Methodol. 2017 Dec 1;17(1):154. doi: 10.1186/s12874-017-0427-0. BMC Med Res Methodol. 2017. PMID: 29191177 Free PMC article.
-
Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):581-595. doi: 10.1007/s10928-021-09753-0. Epub 2021 Apr 21. J Pharmacokinet Pharmacodyn. 2021. PMID: 33884580
-
Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixr.CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):923-930. doi: 10.1002/psp4.12471. Epub 2019 Nov 18. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31654482 Free PMC article.
Cited by
-
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. Br J Clin Pharmacol. 2019. PMID: 31050355 Free PMC article. Clinical Trial.
-
A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression.Antimicrob Agents Chemother. 2015 Sep;59(9):5388-95. doi: 10.1128/AAC.00069-15. Epub 2015 Jun 22. Antimicrob Agents Chemother. 2015. PMID: 26100715 Free PMC article.
-
Evaluation of FOCEI and SAEM Estimation Methods in Population Pharmacokinetic Analysis Using NONMEM® Across Rich, Medium, and Sparse Sampling Data.Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):729-736. doi: 10.1007/s13318-018-0484-8. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29785609
-
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.CPT Pharmacometrics Syst Pharmacol. 2014 Oct 29;3(10):e144. doi: 10.1038/psp.2014.42. CPT Pharmacometrics Syst Pharmacol. 2014. PMID: 25353187 Free PMC article.
-
Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7.J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):223-38. doi: 10.1007/s10928-014-9359-z. Epub 2014 May 7. J Pharmacokinet Pharmacodyn. 2014. PMID: 24801864
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources